11 September 2018
A new report by visiongain predicts the worldwide biosimilar drugs market will generate revenues of $18.42 billion in 2020. That market holds great potential for expansion from 2016 to 2026. Revenue forecasts and discussions on that market appear in Biosimilars and Follow-On Biologics’ Trends, R&D and Revenue Forecasts 2016-2026: Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones. That updated, expanded study appears in February 2016. Visiongain is a business information publisher and consultancy in London, UK.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Biologics are crucial for the treatment of many serious chronic disorders such as cancer, diabetes, hepatitis and autoimmune diseases. However, those effective but highly complex therapies come at a price, with some treatments costing more than $75,000 a year. Biosimilars can offer the benefits of branded biologic therapies, but at a lower price, making them more affordable for individual patients, as well as entire nations in the face of declining healthcare budgets.
“With patents for many blockbuster biologics due to expire over the next ten years, the biosimilars market is set to grow exponentially between now and 2026. However, it will face many challenges along the way, including opposition from originator companies, expensive and lengthy development times and fragmentation in the market. Nevertheless, as the long-awaited approval of the first biosimilar in the US in 2015 shows, biosimilars are here to stay, and their rise to prominence is just beginning.”
Visiongain’s new analysis gives revenue forecasts to 2026 for the overall world biosimilars market. It also provides revenue predictions from 2016 to 2026 for the following eight segments of that market:
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Erythropoietin (EPO)
• Granulocyte colony-stimulating factor (G-CSF)
• Growth hormones
• Fertility hormones.
That report also shows revenue forecasts to 2026 for 12 individual submarkets within those segments:
• Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
• Human insulin, insulin analogues, insulin glargine and insulin lispro
• Interferon alfa and interferon beta
Visiongain’s investigation also contains forecasts and discussions to 2026 for 12 national biosimilar markets:
• Germany, France, UK, Italy and Spain
• China, India, South Korea, Russia and Brazil.
In addition that report shows interviews with authorities from Boehringer Ingelheim and PROBIOMED. It also discusses forces driving and restraining that industry, including research and development. That work shows what the future holds for those medicines.
Biosimilars and Follow-On Biologics’ Trends, R&D and Revenue Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio analyses pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.